Tailored pre-transplant therapy improves survival rate in rare immune deficiency

The Chronic Granulomatous Disease is known as rare immune deficiency that affects organ function and could be a life-threatening disease. This disease has been a real cause of worry for the scientist. Cell transplantation is the only available treatment to this disease. Chemotherapy is available before transplantation but it involves other risk affecting different walks of life. According to new study published in journal The Lancet suggested the pre-transplant drug therapy that will help to boosts the survival rates to over 90 per cent. This will be a real advancement in the field. This will be a relief to the patients as the transplantation is usually not with their family members. This particular process has come up as a new hope for to the patients. Tayfun Güngör, Assistant Professor of Pediatric Stem Cell Transplantation at the University Children's Hospital Zürich, explains, “By tailoring doses of busulfan and carefully sampling patients, we achieved a survival rate of 93 per cent with minimal adverse reaction, independent of the age of the patient, even in those with poor prognosis or highly at risk of graft failure and mortality.”